You have 9 free searches left this month | for more free features.

nnc0174-0833

Showing 1 - 7 of 7

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Obesity, Overweight Trial in Overland Park (NNC0174-0833, Semaglutide, Placebo (NNC0174-0833))

Completed
  • Obesity
  • Overweight
  • NNC0174-0833
  • +2 more
  • Overland Park, Kansas
    Novo Nordisk Investigational Site
Nov 16, 2021

Overweight, Obesity Trial in Montreal (NNC0174-0833, Oral contraceptive (OC) tablets, Acetaminophen)

Completed
  • Overweight
  • Obesity
  • NNC0174-0833
  • +2 more
  • Montreal, Quebec, Canada
    Novo Nordisk Investigational Site
Jan 6, 2022

Overweight, Obesity Trial in Miami, Orlando (NNC0174-0833)

Completed
  • Overweight
  • Obesity
  • NNC0174-0833
  • Miami, Florida
  • +1 more
Jan 25, 2021

Overweight, Obesity Trial in Worldwide (NNC0174-0833, Placebo (NNC0174-0833), Liraglutide 3.0 mg)

Completed
  • Overweight
  • Obesity
  • NNC0174-0833
  • +3 more
  • Anaheim, California
  • +53 more
Feb 24, 2022

Obesity, Overweight Trial in Glendale (NNC0174-0833, Placebo (NNC0174-0833))

Completed
  • Obesity
  • Overweight
  • NNC0174-0833
  • Placebo (NNC0174-0833)
  • Glendale, California
    Novo Nordisk Investigational Site
Jun 21, 2019

Metabolism and Nutrition Disorder, Obesity Trial in Overland Park (NNC0174-0833, Placebo)

Completed
  • Metabolism and Nutrition Disorder
  • Obesity
  • NNC0174-0833
  • Placebo
  • Overland Park, Kansas
    Novo Nordisk Investigational Site
Jan 31, 2018

Metabolism and Nutrition Disorder, Obesity Trial in Overland Park (NNC0174-0833, )

Completed
  • Metabolism and Nutrition Disorder
  • Obesity
  • NNC0174-0833
  • placebo
  • Overland Park, Kansas
    Novo Nordisk Investigational Site
Jan 23, 2018